Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Nondrug
Route of Administration: Sublingual,Injection,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Canada | Czech | Denmark | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Korea | Luxembourg | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Sweden | Switzerland | Turkey | Ukraine | United States
Approved Indications: None
Known Adverse Events: None
Company: Probelte Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Spain
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Asthma, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic
Phase 2: Conjunctivitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PROACAROS | P3 |
Recruiting |
Environmental Hypersensitivity|Dust mite Hypersensitivity |
2026-06-01 |
|
2018-003427-11 | P3 |
Active, not recruiting |
Asthma, Allergic|Rhinitis, Allergic |
2023-10-07 |
|
TiME (short allergen immunotherapy mites) | P2 |
Completed |
Asthma, Allergic|Conjunctivitis, Allergic|Rhinitis, Allergic |
2023-02-04 |